Extremely Preterm Infant Admissions Within the SafeBoosC-III Consortium During the COVID-19 Lockdown

Objective: To evaluate if the number of admitted extremely preterm (EP) infants (born before 28 weeks of gestational age) differed in the neonatal intensive care units (NICUs) of the SafeBoosC-III consortium during the global lockdown when compared to the corresponding time period in 2019. Design: This is a retrospective, observational study. Forty-six out of 79 NICUs (58%) from 17 countries participated. Principal investigators were asked to report the following information: (1) Total number of EP infant admissions to their NICU in the 3 months where the lockdown restrictions were most rigorous during the first phase of the COVID-19 pandemic, (2) Similar EP infant admissions in the corresponding 3 months of 2019, (3) the level of local restrictions during the lockdown period, and (4) the local impact of the COVID-19 lockdown on the everyday life of a pregnant woman. Results: The number of EP infant admissions during the first wave of the COVID-19 pandemic was 428 compared to 457 in the corresponding 3 months in 2019 (−6.6%, 95% CI −18.2 to +7.1%, p = 0.33). There were no statistically significant differences within individual geographic regions and no significant association between the level of lockdown restrictions and difference in the number of EP infant admissions. A post-hoc analysis based on data from the 46 NICUs found a decrease of 10.3%in the total number of NICU admissions (n = 7,499 in 2020 vs. n = 8,362 in 2019). Conclusion: This ad hoc study did not confirm previous reports of a major reduction in the number of extremely pretermbirths during the first phase of the COVID-19 pandemic. Clinical Trial Registration: ClinicalTrial.gov, identifier: NCT04527601 (registered August 26, 2020), https://clinicaltrials.gov/ct2/show/NCT04527601.

[1]  S. Lorch,et al.  Changes in Preterm Birth Phenotypes and Stillbirth at 2 Philadelphia Hospitals During the SARS-CoV-2 Pandemic, March-June 2020. , 2020, JAMA.

[2]  C. Dunne,et al.  Unprecedented reduction in births of very low birthweight (VLBW) and extremely low birthweight (ELBW) infants during the COVID-19 lockdown in Ireland: a ‘natural experiment’ allowing analysis of data from the prior two decades , 2020, BMJ Global Health.

[3]  A. Dorn COVID-19 and readjusting clinical trials , 2020, The Lancet.

[4]  Aaron van Dorn COVID-19 and readjusting clinical trials , 2020, The Lancet.

[5]  D. Hougaard,et al.  Danish premature birth rates during the COVID-19 lockdown , 2020, Archives of Disease in Childhood.

[6]  J. Lawn,et al.  Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study , 2020, The Lancet Global Health.

[7]  I. Reiss,et al.  Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study , 2020, The Lancet Public Health.

[8]  C. Dunne,et al.  Reduction in preterm births during the COVID-19 lockdown in Ireland: a natural experiment allowing analysis of data from the prior two decades. , 2020, medRxiv.

[9]  G. Dimitriou,et al.  Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial , 2019, Trials.

[10]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[11]  A. Akobeng Understanding type I and type II errors, statistical power and sample size , 2016, Acta paediatrica.

[12]  A. Banerjee,et al.  Hypothesis testing, type I and type II errors , 2009, Industrial psychiatry journal.

[13]  T. Hale,et al.  Oxford COVID-19 Government Response Tracker , 2020 .

[14]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[15]  Isabelle Boutron,et al.  A revised tool for assessing risk of bias in randomized trials , 2016 .